Highest-materiality recent filing
Operating expenses declined ~30% YoY to approximately $2.28 million for Q1 2026.
Ainos FY2025 revenue up 499%, gross margin 82.9%; AI Nose deployments scaling in semiconductor
Revenue up ~499% YoY; gross margin improved to 82.9% from a gross loss in 2024.
Ainos grants distribution rights to Trusval Technology for AI Nose products
Three-year distribution agreement with Trusval Technology Co. Ltd. for AINOS AI Nose and related products.
Proprietary AI Nose hardware generates repeatable scent data for large-scale AI training.
Ainos issues 1.16M shares of common stock to wholly owned subsidiary ScentAI
Issued 1,160,000 shares of AIMD common stock to ScentAI Inc. in exchange for 116,000,000 ScentAI shares.
Ainos Q3 2025 results omit financials; focuses on AI Nose partnerships and patents
No net revenue or EPS disclosed in Q3 2025 press release; SG&A down 22% YoY, total opex down 8%.
Ainos extends patent license fee term to two years at $50,000/month with TCNT
Fourth addendum to Product Development Agreement with Taiwan Carbon Nano Technology (TCNT) signed Oct 15, 2025.
Ainos files prospectus supplement for $874,496 ATM stock offering
Company filed prospectus supplement on Sept 5, 2025 to sell up to $874,496 in common stock via ATM agreement with H.C. Wainwright.
Ainos Q2 2025 results highlight $2.1M AI Nose order and commercial momentum
Secured $2.1M three-year subscription order from ASEH for AI Nose in semiconductor manufacturing.
Ainos secures $2.1M order with ASE for AI Nose deployment in semiconductor manufacturing
Three-year subscription order valued at $2.1M from ASE Technology Holding, the world's largest semiconductor assembly and test provider.
Ainos appoints new auditor YCM CPA after KCCW resignation
KCCW resigned as independent auditor on July 30, 2025, citing exit from public company audit practice.
Ainos regains Nasdaq compliance; sets 90-day AI Nose scale plan with 412% Q1 revenue jump
Nasdaq confirmed compliance on July 15, 2025; closing bid price >= $1.00 for 10 consecutive days.
Ainos effects 1-for-5 reverse stock split effective June 30, 2025
Reverse stock split at 1:5 ratio effective 5:01 a.m. Central on June 30, 2025.
Ainos forms strategic partnership with Kenmec to deploy AI Nose in smart factories
Legally binding strategic partnership announced June 24, 2025.
Revenue up 412% YoY to $106,207; gross profit of $87,974 vs prior-year gross loss of $6,025.
Ainos extends maturity of $1M convertible note to May 13, 2025
Original $1,000,000 convertible note issued March 13, 2023 with 6% compounded interest.
Ainos amends convertible note: maturity extended to 2027, conversion price floor lowered to $4.50
Maturity extended from ~March 2025 to March 12, 2027; principal $2M at 6% compounded interest unchanged.
Ainos signs MOU with ASE to deploy AI Nose for semiconductor VOC detection
Ainos (AIMD) and Advanced Semiconductor Engineering (ASE) signed a legally binding MOU to integrate AI Nose into ASE's 46 fully automated factories.
Ainos reports FY2024 revenue $20,729, net loss $14.9M; AI Nose and VELDONA progress
Revenue fell 83% YoY to $20,729; cost of revenues $52,595; gross loss narrowed to $31,866.
Ainos partners with ugo to integrate AI Nose into robots for scent detection
Ainos (AIMD) and ugo, Japan's largest service robot firm, to develop first smell-enabled robot.
Ainos signs non-binding MOU with Taiwan Tanabe for VELDONA manufacturing and Taiwan market
Non-binding MOU with Taiwan Tanabe Seiyaku (Mitsubishi Tanabe subsidiary) for exclusive marketing, manufacturing, and marketing authorization of VELDONA in Taiwan.
Third Addendum to Product Development Agreement adds nitrogen-oxygen separation machine for medical oxygen and wound healing.
Ainos shareholders ratify auditor, approve 2M share special stock award at annual meeting
Ratification of KCCW Accountancy Corp. as auditor approved with 5,062,909 for, 52,319 against.
Issued 5.5M shares to TCNT for exclusive, irrevocable, perpetual license of gas-sensor and medical-device patents.
Ainos Q2 2024 net loss widens to $3.2M; revenues nil; FCGS trial begins
Revenues nil vs $28,555 YoY as COVID-19 test kit sales ceased; net loss $3,195,022 vs $2,349,727.
Ainos receives Nasdaq deficiency notice for bid price below $1; 180 days to cure
Nasdaq notified Ainos that its common stock bid price closed below $1.00 for 30 consecutive business days.
Ainos extends patent license with TCNT for three months at $95k/month
Second Addendum extends non-exclusive patent use for VOC/POCT tech from July to Sept 2024.
Clinical trials for AI Nose-powered Ainos Flora achieved 75 meaningful case results, validating AI algorithm model.
Ainos Q1 revenue down 58% YoY to $20.7K; net loss widens to $3.3M; secures $9M convertible note
Revenue of $20,729 in Q1 2024, down 58% from $49,164 in Q1 2023, due to pivot from COVID-19 test kits.
Ainos issues $9M convertible note to ASE Test, with warrant for 500k shares
$9,000,000 convertible note, 6% compound interest, matures May 3, 2027.
Ainos appoints Christopher Hsin-Liang Lee as CFO, effective March 18, 2024
Mr. Lee named CFO; over 25 years of accounting/finance experience including 10 years as CFO of a Nasdaq-listed company.
CFO Meng-Lin Sung resigns effective March 13, 2024; no replacement named
Meng-Lin Sung resigned as CFO of Ainos, Inc. effective March 13, 2024.
As of August 9, 2024, Lawrence K. Lin transitioned from his role as the Company’s Executive Vice President of Operations, effective August 9, 2024.
On March 15, 2024, the Board of Directors appointed Christopher Hsin-Liang Lee as the Chief Financial Officer of Ainos, Inc. (the “Company”).
On March 13, 2024, Meng-Lin Sung, the Chief Financial Officer of Ainos, Inc. (the “Company”), resigned from her positions with the Company, effective as of such date.
Max materiality 0.75 · Median 0.57 · Most common event other_material